The Highest-Rated Biopharma Stocks

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, the 10 stocks below are the highest rated in the biopharma industry.

CAPS contains more than just the crowd's opinions. The votes of CAPS' best-performing members, known as All-Stars, count more in shaping each company's rating than do the picks of their poorer-performing peers. That way, the highest-rated companies are not just the most popular companies in the industry, in this case MannKind (NAS: MNKD) , but are the best of the best. You can then intelligently use members' collective wisdom to make better decisions and find hidden gems you may never have otherwise heard of.

The biopharma industry has been volatile as ever, with some stocks getting crushed after rejections from the FDA while others have been wildly successful even if it was unexpected.

The highest-rated biopharma stock is...
Looking at the aggregate data, we see that our community rates Celgene (NAS: CELG) above the rest and for good reason. As CAPS player santuse wrote last month:

Celgene is the only major corp. in its sector which is showing bullish trends in almost every aspect of its business. With longer lives, diseases such as cancer will become even more prominent. Thus demand of medical professionals and tools will rise.

Here are the rest of the 10 highest-rated companies in the industry along with their CAPS rating:

2Cubist Pharmaceuticals (NAS: CBST) ****$2,251
3Sunesis Pharmaceuticals (NAS: SNSS) ****$61
4Trius Therapeutics****$194
5SciClone Pharmaceuticals (NAS: SCLN) ****$253
6Cytokinetics (NAS: CYTK) ****$81
8Amarin (NAS: AMRN) ****$975
9Alnylam Pharmaceuticals****$338
10Anadys Pharmaceuticals****$210

Source: Motley Fool CAPS as of Nov. 7.

Use the table as a first step to help generate ideas for further research. Having a watchlist of promising companies is a great place to start. We can help you keep tabs on these beloved companies with My Watchlist, our free, personalized stock tracking service. Click here to start now.

At the time this article was published Fool contributor Dan Dzombak holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story